Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 35.57 as of 2026-10-06T18:32:11.957Z.
Consensus retrieved: 2026-10-06T13:55:05.352Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:32:11.957Z.
Quote observation: 2026-10-06T18:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f5440d38f147f42472ad3502ccef0af83b0bc0ea844c0df361be04396bb1fdd1
Forward PE Ratio (35.57) = Dated Quote Price ($10.67) / Consensus Forward EPS ($0.30)
FORWARD PE RATIO
35.57
SECTOR MEDIAN · HEALTHCARE
19.89
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+78.83%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$988.32M
Forward PE Ratio
35.57
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $988.32M | 35.57 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $992.40M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $982.02M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.44M | N/A |
| Vor Biopharma Inc. (VOR)vs › | $997.58M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $968.31M | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 16.49 |
| Immatics N.V. (IMTX)vs › | $1.02B | N/A |
Trailing P/E
15.0
reported TTM EPS
Forward P/E
35.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.30 implies -57.7% EPS decline vs the reported trailing $0.71.
At the dated quote price of $10.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.30 | $0.06 – $0.48 | 4 | 35.6x |
| 2027-12-31 | $-1.75 | $-2.14 – $-1.26 | 4 | n/m |
| 2028-12-31 | $-1.18 | $-1.32 – $-1.09 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
